As shown in this and previous studies, BRAF-KIAA1549 fusions and mutations such as BRAF V600E, IDH1 R132H, and H3 K27M are among the most common types of genetic alteration mutations in pediatric gliomas, and the immunostains for these alterations should be part of the immunohistochemistry (IHC) repertoire of reference labs in LMICs. This evidence concerns the gene IDH1 and glioma.